288 related articles for article (PubMed ID: 25350973)
1. Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Yeni P; Strohmaier KM; Rodgers AJ; Barnard RJ; Nguyen BY; Teppler H;
Antivir Ther; 2015; 20(3):307-15. PubMed ID: 25350973
[TBL] [Abstract][Full Text] [Related]
2. Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences.
Santos JR; Blanco JL; Masiá M; Gutiérrez F; Pérez-Elías MJ; Iribarren JA; Force L; Antela A; Knobel H; Salavert M; López Bernaldo De Quirós JC; Pino M; Paredes R; Clotet B; ;
J Antimicrob Chemother; 2015 Nov; 70(11):3087-95. PubMed ID: 26490727
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Gatell JM; Kumar PN; Rockstroh JK; Schechter M; Markowitz M; Yeni P; Loutfy MR; Lazzarin A; Lennox JL; Strohmaier KM; Wan H; Barnard RJ; Nguyen BY; Teppler H;
Lancet Infect Dis; 2013 Jul; 13(7):587-96. PubMed ID: 23664333
[TBL] [Abstract][Full Text] [Related]
4. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
Wittkop L; Breilh D; Da Silva D; Duffau P; Mercié P; Raymond I; Anies G; Fleury H; Saux MC; Dabis F; Fagard C; Thiébaut R; Masquelier B; Pellegrin I;
J Antimicrob Chemother; 2009 Jun; 63(6):1251-5. PubMed ID: 19336453
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.
Jaeckle M; Khaykin P; Haberl A; De Leuw P; Schüttfort G; Stephan C; Wolf T
Int J STD AIDS; 2016 Nov; 27(13):1170-1179. PubMed ID: 26429890
[TBL] [Abstract][Full Text] [Related]
6. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
[TBL] [Abstract][Full Text] [Related]
7. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
8. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lennox JL; DeJesus E; Lazzarin A; Pollard RB; Madruga JV; Berger DS; Zhao J; Xu X; Williams-Diaz A; Rodgers AJ; Barnard RJ; Miller MD; DiNubile MJ; Nguyen BY; Leavitt R; Sklar P;
Lancet; 2009 Sep; 374(9692):796-806. PubMed ID: 19647866
[TBL] [Abstract][Full Text] [Related]
10. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
[No Abstract] [Full Text] [Related]
12. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
[TBL] [Abstract][Full Text] [Related]
13. Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
Soulié C; Assoumou L; Darty M; Rodriguez C; Donati F; Sayon S; Peytavin G; Valantin MA; Caby F; Schneider L; Canestri A; Costagliola D; Katlama C; Calvez V; Marcelin AG;
J Antimicrob Chemother; 2015 Dec; 70(12):3339-44. PubMed ID: 26396157
[TBL] [Abstract][Full Text] [Related]
14. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
[TBL] [Abstract][Full Text] [Related]
16. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
Caby F; Valin N; Marcelin AG; Schneider L; Andrade R; Guiguet M; Tubiana R; Canestri A; Valantin MA; Peytavin G; Pacanowski J; Morand-Joubert L; Calvez V; Girard PM; Katlama C
Scand J Infect Dis; 2010 Jul; 42(6-7):527-32. PubMed ID: 20222846
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials.
Pichenot M; Deuffic-Burban S; Cuzin L; Yazdanpanah Y
HIV Med; 2012 Mar; 13(3):148-55. PubMed ID: 22107456
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
Gatell JM; Katlama C; Grinsztejn B; Eron JJ; Lazzarin A; Vittecoq D; Gonzalez CJ; Danovich RM; Wan H; Zhao J; Meibohm AR; Strohmaier KM; Harvey CM; Isaacs RD; Nguyen BY;
J Acquir Immune Defic Syndr; 2010 Apr; 53(4):456-63. PubMed ID: 20306554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
